TM Owner Servier
Oncaspar 3.75mg Injection
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Oncaspar contains pegaspargase, a PEGylated (long-acting) form of the enzyme L-asparaginase, which starves leukaemia cells of an amino acid called asparagine that they cannot make for themselves.
- It is used as one component of combination chemotherapy for acute lymphoblastic leukaemia (ALL) in both children and adults, and is also used for patients who have developed an allergy to the shorter-acting, non-PEGylated asparaginase enzyme extracted directly from bacteria.
- Oncaspar's dose strength is expressed in units of enzyme activity rather than in milligrams alone, so the prescribed dose should always be checked in units against the treatment protocol.
- Oncaspar carries a boxed warning covering serious hypersensitivity reactions, dangerous blood clots, pancreatitis, abnormal bleeding or clotting, and liver toxicity, and it is given only in a hospital or specialist cancer centre by a clinician trained to manage these risks, never self-administered.
Side Effects
- Oncaspar carries a boxed warning because it can cause serious, sometimes life-threatening reactions: severe allergic reactions including anaphylaxis, dangerous blood clots (including in the brain's veins), pancreatitis that can be severe or fatal, abnormal bleeding or clotting problems, and liver damage.
- Because of this, patients are watched closely in a monitored setting for at least an hour after each dose, and blood tests check the pancreas, liver, clotting, and blood sugar throughout treatment.
- Common, less severe effects include nausea, vomiting, fever, tiredness, and raised blood sugar.
- Tell the care team immediately about sudden severe stomach pain (possible pancreatitis), hives, swelling, difficulty breathing, unusual bruising or bleeding, or new leg swelling or chest pain, which can signal a blood clot.
- This boxed-warning safety profile is central to how Oncaspar is monitored.
Precautions & Warnings
- Because of its boxed warning, Oncaspar is not given to patients with a history of serious pancreatitis, significant bleeding or clotting problems, or serious liver disease linked to previous asparaginase treatment, and it is stopped immediately if pancreatitis, a severe clot, or serious bleeding develops during treatment.
- Blood glucose, liver function, pancreatic enzymes (amylase and lipase), and clotting studies are monitored regularly, since Oncaspar can raise blood sugar to the point of needing insulin and can alter clotting factors made by the liver.
- Emergency equipment and medicines for treating a severe allergic reaction must be available at every dose, given after prior exposure to asparaginase products.
- Oncaspar can harm a developing baby, so effective contraception is required during treatment for both women and men, and it should not be used in pregnancy or while breastfeeding unless clearly necessary.
Avoid Interactions
- Oncaspar can reduce the liver's ability to clear other medicines and can interfere with proteins the liver normally makes for blood clotting, so it is used with particular caution alongside other medicines that affect bleeding or clotting, such as anticoagulants or aspirin-containing products, since the combined effect on bleeding risk is hard to predict.
- Vincristine and corticosteroids, common partners in ALL chemotherapy regimens, are typically given before or with Oncaspar according to the protocol, as giving vincristine afterwards can increase its toxicity.
- Live vaccines should be avoided during and for some time after chemotherapy that includes Oncaspar, because the immune system is significantly suppressed.
- Because Oncaspar is always given and monitored by an oncology team, all other medicines, supplements, and planned vaccinations should be reviewed with that team rather than being self-managed.
References
Frequently Asked Questions
Oncaspar (pegaspargase) is a chemotherapy medicine used with other drugs to treat acute lymphoblastic leukaemia (ALL) in children and adults. It is also used for patients allergic to standard L-asparaginase.
Oncaspar is given by injection into a muscle or as an intravenous infusion in a hospital or cancer centre, as part of a chemotherapy schedule. It is never self-administered at home.
Oncaspar carries a boxed warning for serious allergic reactions, dangerous blood clots, pancreatitis, abnormal bleeding or clotting, and liver toxicity. You are monitored closely after each dose because of these risks.
Report sudden severe stomach pain, hives or swelling, breathing difficulty, unusual bruising or bleeding, or leg swelling and chest pain right away. These can signal pancreatitis, allergic reaction, or a blood clot.
Your care team checks blood sugar, liver function, pancreatic enzymes, and clotting tests regularly. You are also watched in clinic for at least an hour after each dose in case of an allergic reaction.
No. Oncaspar can harm a developing baby, so effective contraception is required during treatment for both men and women. It should only be used in pregnancy or breastfeeding if clearly necessary.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
